^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GX301

    i
    Other names: GX301 , GX-301, GX 301, telomerase peptide cancer vaccine
    Associations

    News

    Trials
    Company:
    Genovax, Mediolanum Pharma
    Drug class:
    Cytotoxic T lymphocyte stimulant, T-cell stimulant, Telomerase inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. (PubMed, Cancer Immunol Immunother)
    Main objective of this study was to comparatively analyse safety and immunological response to three GX301 regimens in metastatic castration-resistant prostate cancer patients with response/disease stability after docetaxel chemotherapy. These data indicate that GX301 cancer vaccine is safe and immunogenic in metastatic castration-resistant prostate cancer patients. Schedules with high number of administrations should be preferred in future studies due to their better immunological outcome.
    Clinical • P2 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    docetaxel • GX301